Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024

Rhea-AI Summary

Lumos Pharma announced that new analyses from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials will be presented at the 2024 Annual Meeting of the Endocrine Society (ENDO) in Boston from June 1-4, 2024.

The two posters cover significant findings in pediatric growth hormone deficiency treatments. The first, presented by Dr. Fernando Cassorla, focuses on oral LUM-201 and its ability to restore growth hormone secretion in children. The second, by Dr. Adam Stevens, examines how growth responses to LUM-201 depend on the pattern of hormone secretion.

Positive

• Acceptance of Phase 2 trial data for presentation at a major conference validates the significance of Lumos Pharma's research.
• New analyses indicate that oral LUM-201 can restore growth hormone secretion in children with growth hormone deficiency.
• The data show that growth responses to LUM-201 vary based on hormone secretion patterns, providing valuable insights for personalized treatment approaches.

Negative

• The announcement focuses on Phase 2 trial data, indicating that LUM-201 is still in early clinical stages and not yet close to market approval.
• There is no mention of financial improvements or immediate revenue opportunities arising from these findings.
• Continued dependence on successful future trials and regulatory approvals poses inherent risks for investors.

AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for presentation in two posters at the 2024 Annual Meeting of the Endocrine Society (ENDO), to be held in Boston, MA June 1-4, 2024.

Poster Session P069 – Monday June 3, 12:00-1:30 PM ET

• Poster MON-111 : Oral LUM-201 Restores Pulsatile Growth Hormone Secretion and Growth Response in Moderate Pediatric Growth Hormone Deficiency (PGHD): Key Discoveries from Phase 2 of OraGrowtH212 Trial (Fernando Cassorla, MD, Chief of Pediatric Endocrinology, University of Chile, et al)
  

Late-Breaking Poster Session P108 – Monday June 3, 12:00-1:30PM ET

• Poster MON-704: Growth Response to Oral Growth Hormone Secretagogue LUM-201 in Children with Moderate GH Deficiency (GHD) is dependent on the Pattern of Pulsatile GH Secretion Stimulated by LUM-201 (Adam Stevens, MSc, PhD, Lecturer, University of Manchester, et al)
  

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

What are the dates for Lumos Pharma's presentations at ENDO 2024?

Lumos Pharma's presentations will be held on June 3, 2024, from 12:00-1:30 PM ET.

What is the focus of Lumos Pharma's poster MON-111 at ENDO 2024?

Poster MON-111 focuses on the ability of oral LUM-201 to restore pulsatile growth hormone secretion and growth response in children with moderate pediatric growth hormone deficiency.

What does Lumos Pharma's poster MON-704 at ENDO 2024 analyze?

Poster MON-704 analyzes how growth response to LUM-201 in children with moderate growth hormone deficiency depends on the pattern of pulsatile growth hormone secretion.

What is the stock symbol for Lumos Pharma?

The stock symbol for Lumos Pharma is LUMO.

Where will the ENDO 2024 conference be held?

The ENDO 2024 conference will be held in Boston, MA.